ImmunityBio (NASDAQ:IBRX) Stock Price Up 1% – Here’s Why

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price traded up 1% during mid-day trading on Friday . The company traded as high as $9.25 and last traded at $8.70. 45,076,080 shares traded hands during trading, an increase of 5% from the average session volume of 42,903,035 shares. The stock had previously closed at $8.61.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

Analyst Ratings Changes

Several analysts have recently issued reports on the company. BTIG Research upped their price objective on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. HC Wainwright boosted their target price on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Piper Sandler boosted their target price on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Tuesday. Finally, Jefferies Financial Group boosted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.80.

ImmunityBio Stock Performance

The company has a 50 day simple moving average of $4.35 and a two-hundred day simple moving average of $3.07. The firm has a market cap of $8.57 billion, a PE ratio of -21.22 and a beta of 0.16.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 151,967 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the sale, the director directly owned 3,091,604 shares of the company’s stock, valued at $22,259,548.80. This represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christobel Selecky sold 50,000 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The SEC filing for this sale provides additional information. Insiders sold 226,967 shares of company stock valued at $1,531,912 in the last ninety days. 69.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ImmunityBio

Several institutional investors have recently added to or reduced their stakes in IBRX. AQR Capital Management LLC grew its holdings in shares of ImmunityBio by 193.4% during the first quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after buying an additional 29,297 shares in the last quarter. CWM LLC increased its stake in shares of ImmunityBio by 849.2% during the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after acquiring an additional 43,583 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of ImmunityBio during the 2nd quarter worth $70,000. Dillon & Associates Inc. acquired a new stake in ImmunityBio during the 2nd quarter worth approximately $68,000. Finally, Rathbones Group PLC raised its holdings in ImmunityBio by 21.5% in the second quarter. Rathbones Group PLC now owns 117,420 shares of the company’s stock valued at $310,000 after buying an additional 20,800 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.